Emerging DLL3-Targeted Therapies for Extrapulmonary Neuroendocrine Carcinomas

Listen to Dr. Daniel Morgensztern and Dr. Jonathan Strosberg discuss the diagnosis, prognosis, and current limited treatment options for poorly differentiated extrapulmonary neuroendocrine carcinomas, followed by a discussion focusing on emerging DLL3-targeted therapies, including bispecific therapies, antibody–drug conjugates, and CAR T-cell therapies, and their potential roles in improving patient outcomes.